Oncopeptides AB (publ) (STO:ONCO)
Sweden · Delayed Price · Currency is SEK | Market Cap | 972.41M -35.8% |
| Revenue (ttm) | 95.15M +87.0% |
| Net Income | -212.96M |
| EPS | -0.76 |
| Shares Out | 395.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,125,965 |
| Open | 2.440 |
| Previous Close | 2.426 |
| Day's Range | 2.320 - 2.520 |
| 52-Week Range | 1.255 - 6.140 |
| Beta | -1.42 |
| Analysts | Hold |
| Price Target | 2.70 (+9.76%) |
| Earnings Date | Nov 5, 2026 |
About Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydro... [Read more]
Financial Performance
In 2025, Oncopeptides AB's revenue was 71.12 million, an increase of 124.72% compared to the previous year's 31.65 million. Losses were -249.59 million, -12.31% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ONCO stock is "Hold." The 12-month stock price target is kr 2.70, which is an increase of 9.76% from the latest price.
News
Oncopeptides AB Transcript: Study update
Interim analysis in three Cohort I patients confirmed pharmacologically relevant PDC metabolites in tumor tissue, supporting human blood-brain barrier penetration, with a consistent safety profile. Cohort I completion and a Cohort II start are targeted during 2026; further clinical development will require financing.
Oncopeptides AB Press release: Study update
Oncopeptides AB issued a press release on October 12, 2026, disclosing material business information to investors.
Oncopeptides AB Earnings Call Transcript: Q2 2026
Q2 2026 saw 62% revenue growth and a 98% gross margin, with strong commercial momentum in Germany, Italy, and Spain. Cash reserves were strengthened, and key regulatory and partnership milestones were achieved, supporting the path to positive cash flow in 2027.
Oncopeptides AB Quarterly report: Q2 2026
Oncopeptides AB has published its Q2 2026 quarterly earnings report on August 27, 2026.
Oncopeptides AB Slides: Q2 2026
Oncopeptides AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 27, 2026.
Oncopeptides AB Slides: FY 2026
Oncopeptides AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 9, 2026.
Oncopeptides AB Earnings Call Transcript: Q1 2026
Q1 2026 saw 91% revenue growth and a 99% gross margin, driven by strong sales in Germany and Italy, while Spain lagged. Expansion into third-line treatment and glioblastoma, plus a SEK 200 million rights issue, position the company for further growth.
Oncopeptides AB Quarterly report: Q1 2026
Oncopeptides AB has published its Q1 2026 quarterly earnings report on May 13, 2026.
Oncopeptides AB Slides: Q1 2026
Oncopeptides AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Oncopeptides AB Transcript: Investor update
Plans to expand Pepaxti's indication to third-line multiple myeloma in Europe could double the addressable patient population and treatment cycles, supported by strong OCEAN study data. Regulatory submission is expected soon, with no change to the 2027 cashflow-positive target.
Oncopeptides AB Press release: Investor update
Oncopeptides AB issued a press release on May 11, 2026, disclosing material business information to investors.
Oncopeptides AB Slides: Investor update
Oncopeptides AB has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Oncopeptides AB Slides: FY 2026
Oncopeptides AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 17, 2026.
Oncopeptides AB Slides: FY 2026
Oncopeptides AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 10, 2026.
Oncopeptides AB Earnings Call Transcript: Q4 2025
Net sales more than doubled year-over-year, driven by strong performance in Italy and robust gross margins, though growth in Germany and Spain was hampered by market access issues and external disruptions. A SEK 200 million rights issue will fund continued commercialization and pipeline expansion, with a focus on glioblastoma.
Oncopeptides AB Quarterly report: Q4 2025
Oncopeptides AB has published its Q4 2025 quarterly earnings report on February 19, 2026.
Oncopeptides AB Slides: Q4 2025
Oncopeptides AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 19, 2026.
Oncopeptides AB Annual report: Q4 2025
Oncopeptides AB has published its Q4 2025 annual report on February 19, 2026.
Oncopeptides AB Transcript: Trading update
Q4 2025 sales grew 88% year-over-year, led by Italy, but Spain's doctor strike and German market challenges delayed profitability expectations to 2027. Strategic cost optimization, regional focus, and global partnerships are underway, with glioblastoma R&D prioritized.
Oncopeptides AB Earnings release: Trading update
Oncopeptides AB released its earnings on January 16, 2026, summarizing the period's financial results.
Oncopeptides AB Slides: Trading update
Oncopeptides AB has posted slides in relation to its latest quarterly earnings report, which was published on January 16, 2026.
Oncopeptides AB Transcript: CMD 2025
Strong sales growth and expanding European market access are underpinned by Pepaxti's unique clinical profile and real-world efficacy. The pipeline features next-generation peptide drug conjugates and NK cell engagers, targeting oncology and autoimmune diseases, with global partnerships and preclinical progress supporting long-term growth.
Oncopeptides AB Earnings Call Transcript: Q3 2025
Q3 2025 saw net sales surge 174% year-over-year, with strong growth in Italy and Spain and robust gross margins. A successful rights issue strengthened liquidity, and the company remains on track for profitability by end-2026, with global expansion and scientific recognition advancing.
Oncopeptides AB Quarterly report: Q3 2025
Oncopeptides AB has published its Q3 2025 quarterly earnings report on November 5, 2025.
Oncopeptides AB Slides: Q3 2025
Oncopeptides AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 5, 2025.